Brief: Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data For Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-Her2-Adc, In Treating Heavily Pretreated Her2-Positive Breast Cancer Patients
03/05/2022 14:32
May 3 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* LEVENA BIOPHARMA, A SORRENTO COMPANY, ANNOUNCES POSITIVE
CLINICAL DATA FOR ITS OUT-LICENSED A166 PRODUCT CANDIDATE, A
THIRD-GENERATION ANTI-HER2-ADC, IN TREATING HEAVILY PRETREATED
HER2-POSITIVE BREAST CANCER PATIENTS
Source text for Eikon: ID:nGNX6vWJxK
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20